Q2-osavuosiraportti
91 päivää sitten‧36 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
193
Myynti
Määrä
214
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 303 | - | - | ||
| 247 | - | - | ||
| 111 | - | - | ||
| 2 | - | - | ||
| 291 | - | - |
Ylin
17,2VWAP
Alin
16,6VaihtoMäärä
0,2 10 712
VWAP
Ylin
17,2Alin
16,6VaihtoMäärä
0,2 10 712
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 20.5. | |
| 2024 Q4-osavuosiraportti | 20.2. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14.9.@tisdagscaset on Instagram has done a review of the company! Recommend
·14.7.A little disturbing to the eye to see 0.10% short selling in this company... Maybe it has minimal impact. I think the product seems promising, just that it has to go all the way to the market and become easily accessible to the consumer. Long road, but maybe there are opportunities here... Anyone who has nerded out more about the company?
·18.9.In phase III, patients are not selected randomly, but are first screened. This is done to only include those who meet strict criteria (age, diagnosis, other diseases/medications, etc.), so that the results are reliable and safe. The number of participants depends on the disease, but often involves several hundred to thousands of patients.- ·16.6.Cinclus Pharma receives exemption from pediatric studies – important step for H. pylori project Cinclus Pharma announces today that both the EMA and the FDA have granted exemptions from the requirement to conduct pediatric studies for linaprazan glurate in the treatment of H. pylori infection. This is a regulatory milestone that both simplifies and speeds up the process towards approval. Linaprazan glurate could become a new treatment option for H. pylori – an infection that affects over half of the world’s population and where antibiotic resistance is a growing problem. The drug has the potential to be at least as effective as current treatments, but with only a narrow-spectrum antibiotic, which reduces the risks of resistance. A possible launch for this indication would also extend data exclusivity to 10 years in the US and 11 years in the EU. Cinclus retains global rights outside of China for this particular indication. Exciting development and important validation from both EMA and FDA.
- ·12.6.Cinclus Pharma – undervalued candidate with high potential after FDA breakthrough Think Cinclus Pharma deserves more attention after the development of recent weeks. The company is developing linaprazan glurate – a new type of stomach ulcer medicine (P-CAB) against, among other things, GERD. It is an area where many suffer, and today's treatment (PPI) is far from perfect. What makes it extra interesting right now: The FDA recently approved a competitor's P-CAB in the US (Phathom). This is seen as a clear positive signal value for Cinclus as well. According to Redeye and Carnegie, it can reduce regulatory uncertainty and provide security around the patent landscape. Redeye values the share at SEK 50 in the base scenario, which is almost 3x from today's level (around SEK 17–18). The license agreement with Zentiva covers the entire EU/EEA and UK. This shows that the pharmaceutical industry believes in the technology – and provides the opportunity for future revenue without Cinclus having to build a sales force themselves. Phase 3 is underway, with PSI as contracted CRO. This means that the company is on its way to the crucial clinical phase where approval could open the doors to market launch. Reasonable target prices according to analysts and recent events: 3 months: SEK 50 6 months: SEK 60 12 months: SEK 65–75 Analyst consensus is currently around SEK 62, with upside up to SEK 80 in a positive scenario. The price is still trading below SEK 20, which means significant upside if the company continues to deliver as it has done so far. My assessment: high risk as always in biotech, but the combination of regulatory tailwinds, validated partnerships, clear pipeline and low market capitalization makes Cinclus stand out in its sector. The potential is there – the only question is how many will catch up before the next lift.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
91 päivää sitten‧36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14.9.@tisdagscaset on Instagram has done a review of the company! Recommend
- ·14.7.A little disturbing to the eye to see 0.10% short selling in this company... Maybe it has minimal impact. I think the product seems promising, just that it has to go all the way to the market and become easily accessible to the consumer. Long road, but maybe there are opportunities here... Anyone who has nerded out more about the company?·18.9.In phase III, patients are not selected randomly, but are first screened. This is done to only include those who meet strict criteria (age, diagnosis, other diseases/medications, etc.), so that the results are reliable and safe. The number of participants depends on the disease, but often involves several hundred to thousands of patients.
- ·16.6.Cinclus Pharma receives exemption from pediatric studies – important step for H. pylori project Cinclus Pharma announces today that both the EMA and the FDA have granted exemptions from the requirement to conduct pediatric studies for linaprazan glurate in the treatment of H. pylori infection. This is a regulatory milestone that both simplifies and speeds up the process towards approval. Linaprazan glurate could become a new treatment option for H. pylori – an infection that affects over half of the world’s population and where antibiotic resistance is a growing problem. The drug has the potential to be at least as effective as current treatments, but with only a narrow-spectrum antibiotic, which reduces the risks of resistance. A possible launch for this indication would also extend data exclusivity to 10 years in the US and 11 years in the EU. Cinclus retains global rights outside of China for this particular indication. Exciting development and important validation from both EMA and FDA.
- ·12.6.Cinclus Pharma – undervalued candidate with high potential after FDA breakthrough Think Cinclus Pharma deserves more attention after the development of recent weeks. The company is developing linaprazan glurate – a new type of stomach ulcer medicine (P-CAB) against, among other things, GERD. It is an area where many suffer, and today's treatment (PPI) is far from perfect. What makes it extra interesting right now: The FDA recently approved a competitor's P-CAB in the US (Phathom). This is seen as a clear positive signal value for Cinclus as well. According to Redeye and Carnegie, it can reduce regulatory uncertainty and provide security around the patent landscape. Redeye values the share at SEK 50 in the base scenario, which is almost 3x from today's level (around SEK 17–18). The license agreement with Zentiva covers the entire EU/EEA and UK. This shows that the pharmaceutical industry believes in the technology – and provides the opportunity for future revenue without Cinclus having to build a sales force themselves. Phase 3 is underway, with PSI as contracted CRO. This means that the company is on its way to the crucial clinical phase where approval could open the doors to market launch. Reasonable target prices according to analysts and recent events: 3 months: SEK 50 6 months: SEK 60 12 months: SEK 65–75 Analyst consensus is currently around SEK 62, with upside up to SEK 80 in a positive scenario. The price is still trading below SEK 20, which means significant upside if the company continues to deliver as it has done so far. My assessment: high risk as always in biotech, but the combination of regulatory tailwinds, validated partnerships, clear pipeline and low market capitalization makes Cinclus stand out in its sector. The potential is there – the only question is how many will catch up before the next lift.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
193
Myynti
Määrä
214
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 303 | - | - | ||
| 247 | - | - | ||
| 111 | - | - | ||
| 2 | - | - | ||
| 291 | - | - |
Ylin
17,2VWAP
Alin
16,6VaihtoMäärä
0,2 10 712
VWAP
Ylin
17,2Alin
16,6VaihtoMäärä
0,2 10 712
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 20.5. | |
| 2024 Q4-osavuosiraportti | 20.2. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
91 päivää sitten‧36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 20.11. 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 20.5. | |
| 2024 Q4-osavuosiraportti | 20.2. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14.9.@tisdagscaset on Instagram has done a review of the company! Recommend
- ·14.7.A little disturbing to the eye to see 0.10% short selling in this company... Maybe it has minimal impact. I think the product seems promising, just that it has to go all the way to the market and become easily accessible to the consumer. Long road, but maybe there are opportunities here... Anyone who has nerded out more about the company?·18.9.In phase III, patients are not selected randomly, but are first screened. This is done to only include those who meet strict criteria (age, diagnosis, other diseases/medications, etc.), so that the results are reliable and safe. The number of participants depends on the disease, but often involves several hundred to thousands of patients.
- ·16.6.Cinclus Pharma receives exemption from pediatric studies – important step for H. pylori project Cinclus Pharma announces today that both the EMA and the FDA have granted exemptions from the requirement to conduct pediatric studies for linaprazan glurate in the treatment of H. pylori infection. This is a regulatory milestone that both simplifies and speeds up the process towards approval. Linaprazan glurate could become a new treatment option for H. pylori – an infection that affects over half of the world’s population and where antibiotic resistance is a growing problem. The drug has the potential to be at least as effective as current treatments, but with only a narrow-spectrum antibiotic, which reduces the risks of resistance. A possible launch for this indication would also extend data exclusivity to 10 years in the US and 11 years in the EU. Cinclus retains global rights outside of China for this particular indication. Exciting development and important validation from both EMA and FDA.
- ·12.6.Cinclus Pharma – undervalued candidate with high potential after FDA breakthrough Think Cinclus Pharma deserves more attention after the development of recent weeks. The company is developing linaprazan glurate – a new type of stomach ulcer medicine (P-CAB) against, among other things, GERD. It is an area where many suffer, and today's treatment (PPI) is far from perfect. What makes it extra interesting right now: The FDA recently approved a competitor's P-CAB in the US (Phathom). This is seen as a clear positive signal value for Cinclus as well. According to Redeye and Carnegie, it can reduce regulatory uncertainty and provide security around the patent landscape. Redeye values the share at SEK 50 in the base scenario, which is almost 3x from today's level (around SEK 17–18). The license agreement with Zentiva covers the entire EU/EEA and UK. This shows that the pharmaceutical industry believes in the technology – and provides the opportunity for future revenue without Cinclus having to build a sales force themselves. Phase 3 is underway, with PSI as contracted CRO. This means that the company is on its way to the crucial clinical phase where approval could open the doors to market launch. Reasonable target prices according to analysts and recent events: 3 months: SEK 50 6 months: SEK 60 12 months: SEK 65–75 Analyst consensus is currently around SEK 62, with upside up to SEK 80 in a positive scenario. The price is still trading below SEK 20, which means significant upside if the company continues to deliver as it has done so far. My assessment: high risk as always in biotech, but the combination of regulatory tailwinds, validated partnerships, clear pipeline and low market capitalization makes Cinclus stand out in its sector. The potential is there – the only question is how many will catch up before the next lift.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
193
Myynti
Määrä
214
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 303 | - | - | ||
| 247 | - | - | ||
| 111 | - | - | ||
| 2 | - | - | ||
| 291 | - | - |
Ylin
17,2VWAP
Alin
16,6VaihtoMäärä
0,2 10 712
VWAP
Ylin
17,2Alin
16,6VaihtoMäärä
0,2 10 712
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 10 905 | 10 905 | 0 | 0 |